Psy4 - Response to Induction Therapy, Treatment Adverse Events and Healthcare Resource Use in Incident Anca-Associated Vasculitis (Aav) Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2581
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy78 - The Economic and Healthcare Burden of Anca-Associated Vasculitis (Aav) in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy5 - Patients With Relapsing Anca-Associated Vasculitis (Aav) Experience Unmet Needs and Utilise Significant Healthcare Resources

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

AB0597 Low-Dose Rituximab as Induction Therapy for Japanese Patients With Anca-Associated Vasculitis

2017English

Venous Thrombotic Events in ANCA-associated Vasculitis: Incidence and Risk Factors

Kidney360
2020English

Anca-Associated Vasculitis

The Journal of scientific articles Health and Education millennium
2018English

Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

Kidney International Reports
Nephrology
2018English

Genetics of ANCA-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
2019English

Should Rituximab Be Used to Prevent Relapse in Patients With ANCA-Associated Vasculitis?

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy